The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.b

Pericardial effusion (w/wo tamponade)

Needs be separated from radiation-induced pericardial effusion, underlying disease progression, and from an infection

Publications

Fernández Madrigal L, Montero Pérez O, Rodriguez Garcés MY, Inoriza Rueda Á, Martínez Marcos FJ

Pericardial effusion with pembrolizumab.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2022;28(7):1664-1670

Harada K, Ogasawara M, Shido A, Meno A, Oda S, Yoshida S, Yoshida S, Yoshikawa A, Ebata K, Abiko S, Kawagishi N, Sano I, Oda H, Miyagishima T

Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.

Thoracic cancer. 2020;11(5):1350-1353

Atallah-Yunes SA, Kadado AJ, Soe MH

Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review.

Current problems in cancer. 2019;43(5):504-510